1RT Stock Chart & Stats
€0.02
<€0.01(58.33%)
At close: 4:00 PM EST
€0.02
<€0.01(58.33%)
Day’s Range― - ―
52-Week Range€0.02 - €0.02
Previous CloseN/A
Volume90.00K
Average Volume (3M)90.00K
Market Cap
€4.42M
Enterprise Value€2.97M
Total Cash (Recent Filing)€930.28K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)4.8
Beta-1.03
Next Earnings
Feb 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume90,000
30 Day Avg. Volume90,000
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero DebtZero reported debt materially reduces fixed financial obligations and interest burden, preserving flexibility to finance drug development via equity or partnerships. For a pre-revenue biotech, low leverage lowers bankruptcy risk and lengthens effective runway for strategic initiatives.
Proprietary Cocrystal Technology PlatformA platform that can improve API properties is a structural competitive asset: it enables multiple reformulation programs, licensing or partnership deals, and leverages existing know-how across indications. Platform-driven revenue diversification can support durable commercial pathways if development succeeds.
Smaller Net Loss In 2025 Vs 2024A materially reduced loss indicates management executed cost controls or program prioritisation, improving operational efficiency. Sustained lower burn improves runway, reduces near-term funding needs and increases optionality for strategic partnerships or milestone-driven financing.
Bears Say
No Revenue GenerationAbsence of meaningful revenue across multiple years shows the company has not commercialised products or secured recurring licensing income. Long-term viability therefore hinges on successful development or external deals, increasing execution risk and potential for dilution before sustainable cash flows.
Persistent Negative Free Cash FlowOngoing cash burn necessitates external funding to sustain R&D and operations, constraining strategic flexibility. Reliance on capital raises can lead to dilution, delay programs, and make long-term planning dependent on market access or partner funding rather than self-funded progression.
Shrinking Equity And Small Asset BaseA reduced equity base and small asset footprint weaken the balance sheet cushion against setbacks and limit borrowing or strategic M&A flexibility. For a development-stage biotech this increases vulnerability to trial delays or failed partnerships and raises probability of near-term capital dependence.
Nuformix Plc News
1RT FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest stock price was €0.02 and its highest was €0.02 in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is €4.42M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Feb 03, 2027 which is in 177 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in DE:1RT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―